Skip to main content
Premium Trial:

Request an Annual Quote

mRNA-Seq, FinchLab

Premium
Illumina has launched mRNA-Seq, a product for full-length cDNA sequencing on its Genome Analyzer. Researchers can use mRNA-Seq to generate a full-sequence from any poly-A tailed RNA, allowing them to discover and profile novel transcripts, novel isoforms, alternative splice sites, rare transcripts, and cSNPs. To support the large quantities of data generated using mRNA-Seq, Illumina said it plans to launch a data analysis software program called GenomeStudio in November.
 

 
Geospiza has released a new version of its FinchLab software, which includes additions for the analysis of next-generation sequencing. The software tracks a sample from experimental design to results, linking sample information to quality control data and analysis results. FinchLab offers preconfigured data analysis pipelines and an application programming interface that researchers can use to develop novel approaches to data analysis. The current release supports the tag profiling, resequencing, transcriptome, and ChIP-Seq analysis pipelines for the Illumina Genome Analyzer, and tag profiling and transcriptome analysis pipelines for the Applied Biosystems SOLiD system. It also contains improvements for Roche 454 workflows and many aspects of the lab management system. The next release, planned for November, will include additional analysis capabilities for SOLiD and 454.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.